Quick Answer
Altimmune, Inc. reported R&D Expense of $66.43 million for fiscal year 2025.
Altimmune, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $66.43M | -19.2% |
| 2024 | $82.23M | +25.0% |
| 2023 | $65.80M | -6.7% |
| 2022 | $70.54M | -5.4% |
| 2021 | $74.54M | +49.8% |
| 2020 | $49.77M | +180.2% |
| 2019 | $17.77M | -3.8% |
| 2018 | $18.46M | +0.3% |
| 2017 | $18.41M | +154.9% |
| 2016 | $7.22M | +40.7% |
| 2015 | $5.13M | -44.9% |
| 2014 | $9.32M | -39.0% |
| 2013 | $15.29M | -21.6% |
| 2012 | $19.51M | -8.1% |
| 2011 | $21.22M | +1.6% |
| 2010 | $20.88M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $14.96M | -24.5% | -13.2% |
| June 30, 2025 | $17.24M | -18.5% | +8.9% |
| March 31, 2025 | $15.83M | -26.3% | -20.1% |
| September 30, 2024 | $19.80M | +7.7% | -6.4% |
| June 30, 2024 | $21.16M | +59.6% | -1.5% |
| March 31, 2024 | $21.49M | +24.6% | +16.9% |
| September 30, 2023 | $18.39M | -9.2% | +38.7% |
| June 30, 2023 | $13.25M | -17.1% | -23.2% |
- Altimmune, Inc. showed a decrease of -19.2% in R&D Expense compared to the prior fiscal year.
- Over the 2010–2025 period, Altimmune, Inc.’s r&d expense has grown by 218.2% (from $20.88 million to $66.43 million).
- The most recent figure is from Altimmune, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 6, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: